Inventor · disambiguated record
Jae Woon Son
Also filed as: SON JAE WOON
3 granted patents·7 pending applications·4 citations·filing 2007–2023
53Inventor score
Files withHANALL BIOPHARMA CO LTD3GREEN CROSS CORP2GREEN CROSS HOLDINGS CORP2KIM SUNG WUK2HANALL PHARMACEUTICAL CO LTD1
Top patents by PatentIndex Score
10 records- 0175US8394845B2Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitorKIM SUNG WUK·Filed 2011·Granted Mar 12, 2013·4 cites·10 claims
- 0258US2025099558A1LYOPHILIZED FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE AGREEN CROSS CORP·Filed 2023·Application pending·0 cites
- 0358US2025161211A1LIQUID FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE AGREEN CROSS CORP·Filed 2023·Application pending·0 cites
- 0449US2025367296A1Viscosity-reducing excipient composition and low-viscosity highly concentrated protein formulation containing sameGREEN CROSS HOLDINGS CORP·Filed 2023·Application pending·0 cites
- 0549US2011111022A1Pharmaceutical formulationHANALL BIOPHARMA CO LTD·Filed 2009·Application pending·0 cites
- 0648US2011117194A1Pharmaceutical formulation containing angiotensin-ii receptor blockerHANALL BIOPHARMA CO LTD·Filed 2009·Application pending·0 cites
- 0746US8642083B2Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitorsKIM SUNG WUK·Filed 2007·Granted Feb 4, 2014·0 cites·42 claims
- 0843US2010143470A1Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockersHANALL PHARMACEUTICAL CO LTD·Filed 2007·Application pending·0 cites
- 0936US10815293B2Method for purifying fibrinogenGREEN CROSS HOLDINGS CORP·Filed 2017·Granted Oct 27, 2020·0 cites·13 claims
- 1035US2011212175A1Combination preparation comprising angiotensin-ii-receptor blocker and hmg-coa reductase inhibitorHANALL BIOPHARMA CO LTD·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jae Woon Son files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →